Predicting kidney-related side effects from cancer drugs that block VEGF signals
Official title: Novel Predictors of Vascular Endothelial Growth Factor Signaling Pathway Inhibitor-Associated Proteinuria
Funded at Brigham and Women's Hospital · NIH-11426070 · Data updated 2026-11-12
Aimed at predicting which cancer patients will develop protein in the urine when taking VEGF pathway inhibitors, so doctors can prevent kidney problems and keep cancer treatment on track.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 21, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $881,680 |
| NIH project number | 1R01DK148495-01 |
| Project ID | NIH-11426070 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with cancer who are treated with VEGF signaling pathway inhibitors and are at risk of or currently experiencing proteinuria.
✕Less likely to help
Patients not treated with VEGF inhibitors or those without proteinuria may see no direct benefit.
What this research studies
This project looks at why some patients on VEGF-inhibiting cancer therapies develop proteinuria, a kidney-related side effect. Researchers will use data from thousands of patients treated over several years to build and test a risk-prediction model. The goal is to identify high-risk patients early and guide personalized monitoring and preventive measures. The study combines clinical data, lab results, and genetic information to understand the mechanisms behind this toxicity. If successful, it could help clinicians adjust therapy to reduce kidney injury without compromising cancer control.
Why it matters
Potential benefit: If successful, patients could receive safer cancer treatment with fewer interruptions due to kidney toxicity.
How similar studies have gone: Previous work has shown proteinuria is a common toxicity of VEGF inhibitors, but precise prediction models are not yet established.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Gupta, Shruti — Brigham and Women's Hospital
- Study coordinator: Gupta, Shruti
Related research
Other NIH-funded projects on the same topics.
-
Improving urine protein testing after kidney injury
This study is looking at how to make it easier for doctors to test protein levels in urine after someone has had an acute kidney injury, so they can better manage kidney health and help patients get the care they need.
-
Smartphone app to help follow the 2024 KDIGO chronic kidney disease guidelines
This project will test whether a smartphone app helps young adults (ages 16–29) with chronic kidney disease follow the 2024 KDIGO guideline recommendations.
-
Sparsentan for high-grade proteinuria linked to VEGF inhibitors
This pilot study tests whether sparsentan can reduce severe proteinuria in adults with cancer who are being treated with VEGF signaling pathway inhibitors.
-
Nefecon (budesonide) plus ambrisentan for IgA nephropathy with proteinuria
This test will see if combining Nefecon (a gut‑targeted budesonide) with ambrisentan can reduce urine protein and slow kidney decline in adults with IgA nephropathy who have at least 0.5 g of protein in a 24‑hour urine collection.
-
Effects of Amiloride on Chronic Kidney Disease Progression
This study is testing if the medication amiloride can help people with chronic kidney disease by protecting their kidneys and reducing protein in their urine without changing their blood pressure.
-
Registry and biobank for resistant nephrotic syndrome treatment responses
This study is collecting information from patients with resistant nephrotic syndrome to see how different treatments work and to help find better options for the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.